TY - JOUR
T1 - Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 2
T2 - Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis
AU - Collaborative Ocular Tuberculosis Study Consensus Group
AU - Agrawal, Rupesh
AU - Testi, Ilaria
AU - Bodaghi, Baharam
AU - Barisani-Asenbauer, Talin
AU - McCluskey, Peter
AU - Agarwal, Aniruddha
AU - Kempen, John H.
AU - Gupta, Amod
AU - Smith, Justine R.
AU - de Smet, Marc D.
AU - Yuen, Yew Sen
AU - Mahajan, Sarakshi
AU - Kon, Onn Min
AU - Nguyen, Quan Dong
AU - Pavesio, Carlos
AU - Gupta, Vishali
AU - Agarwal, Mamta
AU - Agarwal, Manisha
AU - Aggarwal, Ashutosh
AU - Aggarwal, Kanika
AU - Agrawal, Mukesh
AU - Al-Dhibi, Hassan
AU - Androudi, Sofia
AU - Asyari, Fatma
AU - Balasundaram, Manohar Babu
AU - Murthy, Kalpana Babu
AU - Baglivo, Edoardo
AU - Banker, Alay
AU - Bansal, Reema
AU - Basu, Soumyava
AU - Behera, Digamber
AU - Biswas, Jyotirmay
AU - Carreño, Ester
AU - Caspers, Laure
AU - Chee, Soon Phaik
AU - Chhabra, Romi
AU - Cimino, Luca
AU - Concha del Rio, Luz Elena
AU - Cunningham, Emmett T.
AU - Land Curi, Andrè Luiz
AU - Das, Dipankar
AU - Davis, Janet
AU - DeSmet, Marc
AU - Denisova, Ekaterina
AU - Denniston, Alastair K.
AU - Errera, Marie Hélène
AU - Fonollosa, Alejandro
AU - George, Amala
AU - Goldstein, Debra A.
AU - Crosier, Yan Guex
AU - Gunasekeran, Dinesh Visva
AU - Gurbaxani, Avinash
AU - Invernizzi, Alessandro
AU - Isa, Hazlita M.
AU - Islam, Shah M.d.
AU - Jones, Nicholas
AU - Katoch, Deeksha
AU - Khairallah, Moncef
AU - Khosla, Amit
AU - Kramer, Michal
AU - Kumar, Amitabh
AU - Kumar, Atul
AU - La Distia Nora, Rina
AU - Lee, Richard
AU - Lowder, Careen
AU - Luthra, Saurabh
AU - Mahendradas, Padmamalini
AU - Makhoul, Dorine
AU - Mazumdar, Shahana
AU - Mehta, Salil
AU - Miserocchi, Elisabetta
AU - Mochizuki, Manabu
AU - Mohamed, Oli S.
AU - Muccioli, Cristina
AU - Munk, Marion R.
AU - Murthy, Somasheila
AU - Narain, Shishir
AU - Nascimento, Heloisa
AU - Neri, Piergiorgio
AU - Nguyen, Myhanh
AU - Okada, Annabelle A.
AU - Ozdal, Pinar
AU - Palestine, Alan
AU - Pichi, Francesco
AU - Raje, Dhananjay
AU - Rathinam, S. R.
AU - Rousselot, Andres
AU - Schlaen, Ariel
AU - Sehgal, Shobha
AU - Nida Sen, H.
AU - Sharma, Aman
AU - Sharma, Kusum
AU - Shoughy, Samir S.
AU - Singh, Nirbhai
AU - Singh, Ramandeep
AU - Soheilian, Masoud
AU - Sridharan, Sudharshan
AU - Thorne, Jennifer E.
AU - Tappeiner, Christoph
AU - Teoh, Stephen
AU - Tognon, Maria Sofia
AU - Tugal-Tutkun, Ilknur
AU - Tyagi, Mudit
AU - Uy, Harvey
AU - Vasconcelos Santos, Daniel Vitor
AU - Valentincic, Natasa Vidovic
AU - Westcott, Mark
AU - Yanai, Ryoji
AU - Alvarez, Bety Yanez
AU - Zahedur, Rahman
AU - Zierhut, Manfred
AU - Xian, Zheng
N1 - Publisher Copyright:
© 2020 American Academy of Ophthalmology
PY - 2021/2
Y1 - 2021/2
N2 - Topic: The Collaborative Ocular Tuberculosis Study (COTS), supported by the International Ocular Inflammation Society, International Uveitis Study Group, and Foster Ocular Immunological Society, set up an international, expert-led consensus project to develop evidence- and experience-based guidelines for the management of tubercular uveitis (TBU). Clinical Relevance: The absence of international agreement on the use of antitubercular therapy (ATT) in patients with TBU contributes to a significant heterogeneity in the approach to the management of this condition. Methods: Consensus statements for the initiation of ATT in TBU were generated using a 2-step modified Delphi technique. In Delphi step 1, a smart web-based survey based on background evidence from published literature was prepared to collect the opinion of 81 international experts on the use of ATT in different clinical scenarios. The survey included 324 questions related to tubercular anterior uveitis (TAU), tubercular intermediate uveitis (TIU), tubercular panuveitis (TPU), and tubercular retinal vasculitis (TRV) administered by the experts, after which the COTS group met in November 2019 for a systematic and critical discussion of the statements in accordance with the second round of the modified Delphi process. Results: Forty-four consensus statements on the initiation of ATT in TAU, TIU, TPU, and TRV were obtained, based on ocular phenotypes suggestive of TBU and corroborative evidence of tuberculosis, provided by several combinations of immunologic and radiologic test results. Experts agreed on initiating ATT in recurrent TAU, TIU, TPU, and active TRV depending on the TB endemicity. In the presence of positive results for any 1 of the immunologic tests along with radiologic features suggestive of past evidence of tuberculosis infection. In patients with a first episode of TAU, consensus to initiate ATT was reached only if both immunologic and radiologic test results were positive. Discussion: The COTS consensus guidelines were generated based on the evidence from published literature, specialists’ opinions, and logic construction to address the initiation of ATT in TBU. The guidelines also should inform public policy by adding specific types of TBU to the list of conditions that should be treated as tuberculosis.
AB - Topic: The Collaborative Ocular Tuberculosis Study (COTS), supported by the International Ocular Inflammation Society, International Uveitis Study Group, and Foster Ocular Immunological Society, set up an international, expert-led consensus project to develop evidence- and experience-based guidelines for the management of tubercular uveitis (TBU). Clinical Relevance: The absence of international agreement on the use of antitubercular therapy (ATT) in patients with TBU contributes to a significant heterogeneity in the approach to the management of this condition. Methods: Consensus statements for the initiation of ATT in TBU were generated using a 2-step modified Delphi technique. In Delphi step 1, a smart web-based survey based on background evidence from published literature was prepared to collect the opinion of 81 international experts on the use of ATT in different clinical scenarios. The survey included 324 questions related to tubercular anterior uveitis (TAU), tubercular intermediate uveitis (TIU), tubercular panuveitis (TPU), and tubercular retinal vasculitis (TRV) administered by the experts, after which the COTS group met in November 2019 for a systematic and critical discussion of the statements in accordance with the second round of the modified Delphi process. Results: Forty-four consensus statements on the initiation of ATT in TAU, TIU, TPU, and TRV were obtained, based on ocular phenotypes suggestive of TBU and corroborative evidence of tuberculosis, provided by several combinations of immunologic and radiologic test results. Experts agreed on initiating ATT in recurrent TAU, TIU, TPU, and active TRV depending on the TB endemicity. In the presence of positive results for any 1 of the immunologic tests along with radiologic features suggestive of past evidence of tuberculosis infection. In patients with a first episode of TAU, consensus to initiate ATT was reached only if both immunologic and radiologic test results were positive. Discussion: The COTS consensus guidelines were generated based on the evidence from published literature, specialists’ opinions, and logic construction to address the initiation of ATT in TBU. The guidelines also should inform public policy by adding specific types of TBU to the list of conditions that should be treated as tuberculosis.
UR - http://www.scopus.com/inward/record.url?scp=85089101945&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2020.06.052
DO - 10.1016/j.ophtha.2020.06.052
M3 - Article
C2 - 32603726
AN - SCOPUS:85089101945
SN - 0161-6420
VL - 128
SP - 277
EP - 287
JO - Ophthalmology
JF - Ophthalmology
IS - 2
ER -